5
The company was approved to market antiretrovirals and malaria medicines such as efavirenz 600 mg; lamivudine 300 mg; tenofovir 300 mg Artemether 20 mg; lumefantrine 120 mg tablets, and tenofovir 300mg/lamivudine 300mg/dolutegravir 50mg (TLD) tablets.
The medicines will be manufactured and delivered to the region effective immediately.
In a media release dated Apr.22, CiplaQCIL's Chief Executive Officer,
"The approval from the regulatory authority not only bestows a vote of confidence in CiplaQCIL but also in
The approval opens doors for CiplaQCIL to gain entry into new markets such as
The company recently upgraded its manufacturing facility to be able to meet the increased volumes following this approval.
"We are proud to be able to produce quality, affordable medicine in
Copyright The Independent. Distributed by AllAfrica Global Media (allAfrica.com)., source